Novocure (Baar, Switzerland) announced today that it has won a CE mark for its Optune Lua wearable device for treating metastatic non-small cell lung cancer. The regulatory approval in the European Union comes approximately six months after Novocure secured FDA approval of the system, which uses tumor-treating fields (TTFields) to kill cancer cells. Through non-invasive, wearable […]
NovoCure
Novocure reports positive trial results for TTFields therapy in pancreatic cancer
Novocure this week announced positive topline results from its Phase 3 trial of its Tumor Treating Fields for pancreatic cancer. The PANOVA-3 trial demonstrated a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated with Tumor Treating Fields (TTFields) therapy with gemcitabine and nab-paclitaxel. Novocure said the trial met […]
Novocure picks successor for CFO taking over corner office
Novocure (Nasdaq:NVCR) announced today that it appointed Christoph Brackmann as its next chief financial officer (CFO). Root, Switzerland-based Novocure plans for Brackmann to join the company immediately as a senior financial advisor. He will transition to the role of CFO on Jan. 1, 2025, when current CFO, Ashley Cordova, becomes CEO. The company announced last […]
Novocure wins FDA nod for lung cancer treatment wearable
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung cancer. Optune Lua uses tumor-treating fields (TTFields) to exert physical forces on the electrically charged components of dividing cancer cells. This results in cell death. The FDA approved the device for concurrent use with PD-1/PD-L1 inhibitors […]
Novocure CEO to step down, CFO Ashley Cordova named as successor
Novocure today announced CEO Asaf Danzinger will resign from his position, effective January 1, 2025. Danzinger has accepted a new role as senior advisor at the cancer treatment tech company, effective on the same date until early 2026. He has served as Novocure’s CEO since 2002. “It has been a special honor and one of […]
Novocure stock dips on Q4 EPS miss
Novocure (Nasdaq:NVCR) shares took a hit today on fourth-quarter results that came in mixed compared to the consensus forecast. Shares of NVCR dipped 4.6% at $78.26 apiece in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — rose 8.1%. The Root, Switzerland-based tumor-treating fields developer […]
Novocure announces leadership team restructuring
Novocure (Nasdaq:NVCR) today announced organizational changes for its leadership team as it prepares for future growth. The company said the changes became effective Jan. 17. Pritesh Shah, Novocure’s chief commercial officer, transitioned into a new role as chief growth officer. His responsibilities include product and portfolio strategy, brand management, launch framework and market access/intelligence. He […]
Novocure beats The Street in Q3
Novocure (Nasdaq:NVCR) shares rose slightly today on third-quarter results that came in ahead of the consensus forecast. The St. Helier, Jersey–based tumor-treating fields developer posted losses of $26.6 million for the quarter. That amounts to losses of 25¢ per share on sales of $131 million for the three months ended Sept. 30, 2022. Novocure registered […]
Novocure sinks on missed Q4 projections
Novocure (NSDQ:NVCR) shares took a sharp dip on fourth-quarter results that came up short of the consensus forecast. NVCR shares were down 12.7% at $63.70 per share in early-morning trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was down 1.3%. The St. Helier, Jersey-based company […]
These medtech companies care a lot about research
They’re making glaucoma-treating stents, tumor-treating fields, coin-sized CGMs and more. Discover the medtech companies that spend the most on research as a percentage of revenue. The list comes from our annual Big 100 report, which examines the world’s 100 largest medical device companies and ranks them by revenue. (Check out our full Big 100 report […]
Novocure signs agreement to build development facility in New Hampshire
Novocure (NSDQ:NVCR) announced today that it signed a purchase and sale agreement for an office building in Portsmouth, New Hampshire. The agreement covers the acquisition and construction of the building at 64 Vaughan Mall, situated centrally in downtown Portsmouth. The purchase price for the property totals $9.5 million and, after closing (expected on or before […]
